Pixelgen Technologies Secures $15.5M Series B Financing to Accelerate Commercialization of Proxiome Kit

Pixelgen Technologies, a developer of high-throughput platform for mapping molecular cell architecture, has successfully closed an oversubscribed $15.5 million Series B financing round. The financing, led by Flat Capital with continued participation from existing investors Industrifonden and Navigare Ventures, aims to accelerate global commercialization of its Proxiome Kit and expand its presence in key markets.

This funding will provide the company with the necessary resources to meet the growing demand for its Proxiome Kit and data analysis and visualization software, as well as to expand its commercial reach, grow its team, and bring molecular cell architecture to more researchers and new applications. The Proxiome Kit, the first platform of its kind, allows high-throughput mapping of molecular cell architecture at nanoscale resolution, thereby offering researchers a new way to study cell function and disease mechanisms.

The addition of Flat Capital CEO Rickard El Tarzi and life sciences industry veteran Ramon Felciano, Ph.D., to its board of directors is expected to bring extensive experience and expertise in investments, strategic development, and board leadership, which will be pivotal in driving Pixelgen's next phase of growth. The company's aim is to build digital capabilities that translate its technical differentiation - the molecular cell architecture platform - into company-level competitive advantage.